fbpx Skip to main content

FRIDAY, Nov. 20, 2020 (HealthDay News) — Lung cancer survival has increased to 22.6 percent nationally, and people of color face worse outcomes than White Americans, according to a report from the American Lung Association published online Nov. 17.

In an effort to provide a picture of the current lung cancer burden in the United States, researchers from the American Lung Association evaluated state-specific measures of lung cancer incidence, five-year survival, early diagnosis, treatments, and screening for those at high risk.

The researchers note that more than 228,000 people will be diagnosed with lung cancer this year, with considerable variation seen in the rate of new cases between states. The rate of new cases decreased 9 percent nationally during the last five years. The national average of people alive five years after a lung cancer diagnosis is 22.6 percent, representing a 13 percent improvement during the last five years. Only 23 percent of cases are diagnosed at an early stage when five-year survival is high (59 percent); 47 percent are not diagnosed until late stages (survival rate, 6 percent). During the last five years, early diagnosis rates increased 33 percent. Nationally, 20.6 percent of those with lung cancer underwent surgery, while 15.2 percent did not receive any treatment. Nationally, only 5.7 percent of those at high risk were screened, with rates varying from 1.0 to 18.5 percent in Nevada and Massachussetts, respectively. People of color are less likely to be diagnosed early and to receive surgical treatment and are more likely to not receive treatment, resulting in worse outcomes compared with Whites.

You May Also Like::  Burden of Medical Costs for Sickle Cell Disease Quantified

In conclusion, the authors of the report note that “lung cancer rates for every measure vary significantly by state, and that every state can do more to defeat lung cancer.”

State of Lung Cancer 2020 Report

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More